Munich, Germany

Axel Ullrich

USPTO Granted Patents = 90 

 

 

Average Co-Inventor Count = 3.1

ph-index = 25

Forward Citations = 3,170(Granted Patents)


Inventors with similar research interests:


Location History:

  • South San Francisco, CA (US) (1990)
  • Munchen, DE (1995 - 2001)
  • M{umlaut over (u)}nchen, DE (2001)
  • Martinsried bei Munich, DE (1996 - 2002)
  • Martimiried, DE (2002)
  • Martinsried bei Muchen, DE (1996 - 2003)
  • Martinsreid, DE (1999 - 2003)
  • Martinsried, DE (1999 - 2004)
  • Portola Valley, CA (US) (1997 - 2006)
  • München 40, DE (2006)
  • Martinreid, DE (2008)
  • Muenchen, DE (2010)
  • San Francisco, CA (US) (1984 - 2013)
  • München, DE (2003 - 2015)
  • Munich, DE (1996 - 2016)

Company Filing History:

goldMedal52 out of 1,288 
 
Max-planck-gesellschaft Zur Forderung Der Wissenschaften E.v.
 patents
silverMedal20 out of 3,221 
 
Genentech, Inc.
 patents
bronzeMedal7 out of 157 
 
Sugen Incorporated
 patents
44 out of 891 
 
Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.
 patents
54 out of 15,458 
 
University of California
 patents
64 out of 1,624 
 
New York University
 patents
72 out of 98 
 
Genetech, Inc.
 patents
82 out of 5 
 
Bio-signal Corporation Ltd.
 patents
91 out of 3 
 
Icrf Patents Limited
 patents
101 out of 1,164 
 
Boehringer Mannheim Gmbh
 patents
111 out of 13 
 
Eberhard-Karls-Universität Tübingen Universitätsklinikum
 patents
121 out of 14 
 
Lead Discovery Center Gmbh
 patents
131 out of 1 
 
Max-flanck-gesellschaft Zuer For{overscore (d)}erung Der
 patent
141 out of 1 
 
Max Planck Gessellschaft
 patent
151 out of 1 
 
Max Planck Gesellschaft Forgerung Der Wissenschaften
 patent
166 out of 832,680 
Other
 patents
where one patent can have more than one assignee

Years Active: 1984-2016

Loading Chart...
Loading Chart...
Loading Chart...
90 patents (USPTO):Explore Patents

Title: Axel Ullrich: Pioneering Researcher in Growth Factor Receptors

Introduction:

Throughout his illustrious career, Axel Ullrich has emerged as a prominent figure in the field of biomedical research. Renowned for his groundbreaking work on growth factor receptors, Ullrich's contributions have significantly advanced our understanding of various diseases, particularly diabetes and cancer. This article explores Ullrich's latest patents, career highlights, collaborations, and his enduring impact on the field of medical innovation.

Latest Patents:

Axel Ullrich's remarkable intellect and ingenuity are showcased through his recent patents. Among these patents are two significant inventions:

1. Method for treatment of diabetes by a small molecule inhibitor for GRK5: Ullrich's invention focuses on a compound capable of modulating the activity and expression of the protein kinase GRK5. This innovation enhances the expression and release of insulin, paving the way for potential treatments for diseases of carbohydrate metabolism, particularly type 2 diabetes.

2. Quinoline derivatives as AXL kinase inhibitors: Ullrich's research encompasses the development of novel compounds that inhibit receptor tyrosine kinases of the AXL receptor family. These compounds hold promise for the treatment or prevention of disorders associated with hyperfunction of AXL receptors, including hyperproliferative disorders like cancer, particularly cancer metastases.

Career Highlights:

Ullrich's remarkable career has spanned various prestigious institutions and organizations, including the following:

1. Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.: Ullrich's affiliation with this renowned scientific institution highlights his commitment to pursuing groundbreaking research. During his tenure, Ullrich spearheaded pivotal studies on growth factor receptors, earning him international recognition in the scientific community.

2. Genentech, Inc.: Ullrich's affiliation with Genentech, a leading biotechnology company, further solidified his position as a leader in the field. Collaborating with other brilliant minds in the company, Ullrich contributed to the development of innovative therapies, particularly in the field of cancer research.

Collaborations:

Throughout his career, Axel Ullrich has worked alongside esteemed colleagues who have further enriched his contributions to scientific advancements. Two notable collaborators include:

1. Robert M. Hudziak: Hudziak's collaboration with Ullrich has yielded significant progress in the field of growth factor receptors. Their collective efforts have paved the way for advancements in understanding the role of these receptors in diseases like diabetes and cancer.

2. H. Michael Shepard: Collaboration with H. Michael Shepard has led to groundbreaking research in the development of targeted therapies for cancer. Together, they have contributed to pioneering treatments that aim to inhibit cancer growth and metastases.

Conclusion:

Axel Ullrich's immense contributions to the fields of growth factor receptors, diabetes, and cancer research have propelled medical innovation forward. With a remarkable number of patents, Ullrich continues to inspire future generations of researchers and inventors. Through his collaborations and affiliations with esteemed institutions and companies like Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. and Genentech, Inc., Ullrich has left an indelible mark on the scientific community. His immense expertise and dedication illustrate the immense potential of innovation and patenting in revolutionizing healthcare and improving the lives of millions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…